

Basic research of prostate cancer



Dear Colleagues,

It is a great honor to set up this special issue on "Basic research of prostate cancer" with the *Journal of Men's Health*. The achievement of the average period of manuscript processing (submission-acceptance), the responsible and positive attitude of the journal are favored by the majority of authors.

Prostate cancer has been one of the most serious malignant diseases threatening the health of men, and its incidence rate and mortality rate are increasing worldwide. The occurrence and development of prostate cancer is a complex process involving many factors. After about 18-24 months of endocrine therapy, most patients will gradually develop into castration resistant prostate cancer (CRPC). The survival prognosis of patients with CRPC is not ideal, the median survival time is less. With the concept of precision medicine and overtreatment proposed, the treatment plan of prostate cancer at different stages also needs to be changed, and patients with localized prostate cancer are more likely to get the opportunity to improve and prolong life. In clinical practice, it is always difficult to screen and treat individualized patients. The progress in the pathogenesis, therapeutic resistance and precision treatment of prostate cancer, et al must rely on basic research.

In recent decades, the basic research of prostate cancer has made important breakthroughs, and the relevant molecular mechanisms are also in-depth excavation. With the accumulation of more and more research results, how to promote the transformation and application of basic research in the clinical diagnosis and treatment of prostate cancer in the future is an important measure to deal with the stubborn disease of prostate cancer. To this end, we set up this special issue, striving to contribute to men's health and the ultimate victory over prostate cancer.



Guest Editor, Xuezhen Yang

MD, PhD, Professor, Executive Vice Chair,
Department of Urology, The Second Affiliated
Hospital of Bengbu Medical College, P.R. China
engineyang@sina.com



Guest Editor, Benyi Li

MD, PhD, Professor, Director of Basic
Science Research, Department of Urology,
University of Kansas Medical Center, USA
BLI@kumc.edu

Keywords: Prostate cancer, Therapeutic resistance, Castration resistant prostate cancer, Molecular etiology, Cell and molecular biology

Submission deadline: 30 November 2021